Intended Use
This product is intended strictly for laboratory research purposes only. It is not approved for human or animal use and must not be used in food, supplements, pharmaceuticals, or cosmetic applications.
THE ULTIMATE CUT
GLP-TRES handles appetite, glucose control, and energy expenditure.
AOD-9604 targets fat metabolism.
For AOD-9604, think of it as a "fat-loss accelerator" rather than an appetite suppressant. The best pairings are usually with peptides that cover the areas AOD doesn't.
5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency.
This product is intended strictly for laboratory research purposes only. It is not approved for human or animal use and must not be used in food, supplements, pharmaceuticals, or cosmetic applications.
(LY3437943) is a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously, engineered with a fatty-acid moiety for an approximately 6 day half-life and once-weekly dosing. Phase 2 trials demonstrated up to 24% body weight reduction at 48 weeks and HbA1c reductions of 1.3 to 2.0% in type 2 diabetes patients. Not FDA-approved; available for research use only.
This product is intended strictly for laboratory research purposes only. It is not approved for human or animal use and must not be used in food, supplements, pharmaceuticals, or cosmetic applications.
No results match your search. Try removing a few filters.
Access is restricted to individuals 21 years of age or older.
